Jesus Castro-Marrero1, Naia Sáez-Francàs2, María Jose Segundo3, Natalia Calvo4, Mónica Faro5, Luisa Aliste5, Tomás Fernández de Sevilla5, Jose Alegre5. 1. CFS Clinical Unit, Vall d'Hebron University Hospital Research Institute, Universitat Autònoma de Barcelona, 08035, Barcelona, Spain. Electronic address: jesus.castro@vhir.org. 2. Psychiatry Unit, Sant Rafael Hospital (FIDMAG), 08035, Barcelona, Spain; Psychiatry Department, Vall d'Hebron University Hospital (CIBERSAM), Universitat Autònoma de Barcelona, 08035, Barcelona, Spain. 3. Vitae Natural Nutrition, S.L., Sant Cugat del Vallès, 08172, Barcelona, Spain. 4. Psychiatry Department, Vall d'Hebron University Hospital (CIBERSAM), Universitat Autònoma de Barcelona, 08035, Barcelona, Spain. 5. CFS Clinical Unit, Vall d'Hebron University Hospital Research Institute, Universitat Autònoma de Barcelona, 08035, Barcelona, Spain.
Abstract
BACKGROUND & AIMS:Chronic Fatigue Syndrome (CFS) is a complex condition, characterized by severe disabling fatigue with no known cause, no established diagnostic tests, and no universally effective treatment. Several studies have proposed symptomatic treatment with coenzyme Q10 (CoQ10) and nicotinamide adenine dinucleotide (NADH) supplementation. The primary endpoint was to assess the effect of CoQ10 plus NADH supplementation on age-predicted maximum heart rate (max HR) during a cycle ergometer test. Secondary measures included fatigue, pain and sleep. METHODS: A proof-of-concept, 8-week, randomized, controlled, double-blind trial was conducted in 80 CFS patients assigned to receive either CoQ10 plus NADH supplementation or matching placebo twice daily. Maximum HR was evaluated at baseline and at end of the run-in period using an exercise test. Fatigue, pain and sleep were evaluated at baseline, and then reassessed at 4- and 8-weeks through self-reported questionnaires. RESULTS: The CoQ10 plus NADH group showed a significant reduction in max HR during a cycle ergometer test at week 8 versus baseline (P = 0.022). Perception of fatigue also showed a decrease through all follow-up visits in active group versus placebo (P = 0.03). However, pain and sleep did not improve in the active group. Coenzyme Q10 plus NADH was generally safe and well tolerated. CONCLUSIONS: Our results suggest that CoQ10 plus NADH supplementation for 8 weeks is safe and potentially effective in reducing max HR during a cycle ergometer test and also on fatigue in CFS. Further additional larger controlled trials are needed to confirm these findings. Clinical trial registrationThis trial was registered at clinicaltrials.gov as NCT02063126.
RCT Entities:
BACKGROUND & AIMS:Chronic Fatigue Syndrome (CFS) is a complex condition, characterized by severe disabling fatigue with no known cause, no established diagnostic tests, and no universally effective treatment. Several studies have proposed symptomatic treatment with coenzyme Q10 (CoQ10) and nicotinamide adenine dinucleotide (NADH) supplementation. The primary endpoint was to assess the effect of CoQ10 plus NADH supplementation on age-predicted maximum heart rate (max HR) during a cycle ergometer test. Secondary measures included fatigue, pain and sleep. METHODS: A proof-of-concept, 8-week, randomized, controlled, double-blind trial was conducted in 80 CFS patients assigned to receive either CoQ10 plus NADH supplementation or matching placebo twice daily. Maximum HR was evaluated at baseline and at end of the run-in period using an exercise test. Fatigue, pain and sleep were evaluated at baseline, and then reassessed at 4- and 8-weeks through self-reported questionnaires. RESULTS: The CoQ10 plus NADH group showed a significant reduction in max HR during a cycle ergometer test at week 8 versus baseline (P = 0.022). Perception of fatigue also showed a decrease through all follow-up visits in active group versus placebo (P = 0.03). However, pain and sleep did not improve in the active group. Coenzyme Q10 plus NADH was generally safe and well tolerated. CONCLUSIONS: Our results suggest that CoQ10 plus NADH supplementation for 8 weeks is safe and potentially effective in reducing max HR during a cycle ergometer test and also on fatigue in CFS. Further additional larger controlled trials are needed to confirm these findings. Clinical trial registrationThis trial was registered at clinicaltrials.gov as NCT02063126.
Authors: Benjamin Heng; Gilles J Guillemin; Bahar Kavyani; Brett A Lidbury; Richard Schloeffel; Paul R Fisher; Daniel Missailidis; Sarah J Annesley; Mona Dehhaghi Journal: Cell Mol Life Sci Date: 2022-07-11 Impact factor: 9.207
Authors: Adonis Sfera; Carolina Osorio; Carlos M Zapata Martín Del Campo; Shaniah Pereida; Steve Maurer; Jose Campo Maldonado; Zisis Kozlakidis Journal: Front Cell Neurosci Date: 2021-06-25 Impact factor: 5.505
Authors: F Ciregia; L Kollipara; L Giusti; R P Zahedi; C Giacomelli; M R Mazzoni; G Giannaccini; P Scarpellini; A Urbani; A Sickmann; A Lucacchini; L Bazzichi Journal: Transl Psychiatry Date: 2016-09-27 Impact factor: 6.222